Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026
Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026
Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026
Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026
Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Drug

Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success

Fineline Cube May 25, 2026

Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and...

Company Drug

Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment

Fineline Cube May 25, 2026

Novo Nordisk A/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use...

Company Medical Device

Hangzhou Diagens Secures NMPA Category III Approval for AI AutoVision Chromosome Karyotyping System

Fineline Cube May 25, 2026

Hangzhou Diagens Biotechnology Co., Ltd. (HKG: 2526) announced it has received Category III medical device...

Company Drug

Biogen, Denali Terminate Parkinson’s Drug BIIB122 After Phase IIb LUMA Study Failure

Fineline Cube May 25, 2026

Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of...

Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Fineline Cube May 24, 2026

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that China’s National Medical Products...

Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Fineline Cube May 24, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that Australia’s Therapeutic Goods Administration (TGA) has granted...

Company Drug

Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors

Fineline Cube May 24, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Fineline Cube May 24, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced positive results from its Phase III and Phase II...

Company Drug

Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2/QX001S in Crohn’s Disease

Fineline Cube May 24, 2026

Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2/QX001S, a biosimilar to Johnson & Johnson’s autoimmune therapy...

Company Drug

3D Medicines Enrolls First Patient in Pivotal Phase III Trial of Envafolimab for Resectable NSCLC

Fineline Cube May 24, 2026

3D Medicines (HKG: 1244) announced the enrollment of the first patient in a Phase III...

Company

Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years

Fineline Cube May 23, 2026

Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced a significant executive leadership reshuffle, with President and...

Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Fineline Cube May 23, 2026

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Medicines Agency’s (EMA) Committee...

Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Fineline Cube May 23, 2026

Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3...

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Fineline Cube May 22, 2026

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the TRIUMPH-1 Phase 3...

Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Fineline Cube May 22, 2026

Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the...

Company Drug

Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU

Fineline Cube May 22, 2026

Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use...

Company Drug

Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC

Fineline Cube May 22, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s Center for Drug Evaluation (CDE)...

Company Drug

Bayer’s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease

Fineline Cube May 22, 2026

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted...

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization...

Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced a strategic alliance with the Abu Dhabi Department...

Posts pagination

1 2 3 4 … 672

Recent updates

  • Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing
  • TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC
  • Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech
  • Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.